MHRA grants PIM designation to UCB's zilucoplan for myasthenia gravis
The UK Medicine and Healthcare Products Regulatory Agency has granted Promising Innovative Medicine (PIM) designation to Belgian drugmaker UCB’s (Euronext: UCB) zilucoplan for the treatment of adults with generalized myasthenia gravis (gMG).
- The granting of a PIM designation is an early indication that an investigational treatment may be made available to patients with life threatening or seriously debilitating conditions where there is a clear unmet medical need, through the Early Access to Medicines Scheme
- This designation makes zilucoplan the first investigational treatment with a published PIM designation for gMG in the UK
- gMG is a rare, chronic auto-immune disease that disrupts the way the nerves communicate with the muscles. There are an estimated 12,000 people in the UK living with the disease, who experience a variety of symptoms because of the condition, including drooping eyelids, double vision, and difficulty swallowing, chewing and eating
Claire Brading, managing director and head of neurology UCB UK & Ireland said: “Myasthenia gravis is a serious condition that can have unpredictable and debilitating symptoms, affecting patients’ lives in multiple ways. We are pleased that zilucoplan has been recognized by the MHRA for its potential to address the urgent need for treatment innovation in this area. This is testament to UCB’s commitment to MG patients in the UK, as well as to harnessing science to bring benefit to people living with rare diseases more widely.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze